Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Keros Therapeutics, Inc. - common stock (NQ:KROS)

15.82 +0.24 (+1.57%)
Streaming Delayed Price Updated: 9:44 AM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Keros Therapeutics, Inc. - common stock

< Previous 1 2 3 Next >
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
BofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor concerns. 
Via Benzinga
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review. 
Via Benzinga
Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price
Things are hog wild at Harley-Davidson; Plus, Impresoft, Keros Therapeutics and Rivalry Corp. are all itching for a deal. 
Via Benzinga
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan
Keros Therapeutics launches strategic review and adopts rights plan after investor activity signals potential changes in company control. 
Via Benzinga
Analyst Expectations For Keros Therapeutics's Future
 
Via Benzinga
Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings)
 
Via Benzinga
Where Keros Therapeutics Stands With Analysts
 
Via Benzinga
Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
These stocks are gapping in today's session
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed
The company said the plan aims to reduce the likelihood of any entity or person gaining control of Keros through open-market accumulation without paying all stockholders an appropriate control... 
Via Stocktwits
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump
 
Via Benzinga
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Forecasting The Future: 7 Analyst Projections For Keros Therapeutics
 
Via Benzinga
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on Behalf of Keros Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS)
From Kirby McInerney LLP
Via Business Wire
Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views
 
Via Benzinga
Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results
 
Via Benzinga
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes
The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence. 
Via Stocktwits
Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS
Via ACCESSWIRE
Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS
Via ACCESSWIRE
Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher
 
Via Benzinga
Topics Stocks
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
 
Via Benzinga
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
 
Via Benzinga
Keros Therapeutics Loses 75% Value In A Single Session - Here's Why
Keros Therapeutics halts high-dose cibotercept treatment in the TROPOS trial after safety concerns, with topline results anticipated in Q2 2025. 
Via Benzinga
Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study
The company is continuing to test the lowest dose of its pulmonary arterial hypertension drug. 
Via Investor's Business Daily
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.